abs46.txt	background		the	majority	of	urothelial	cancers	(uc)	harbor	alterations	inretinoblastoma	(rb)	pathway	genes	that	can	lead	to	loss	of	rb	tumour	suppressorfunction		palbociclib	is	an	oral		selective	inhibitor	of	cdk	4/6	that	restores	rbfunction	and	promotes	cell	cycle	arrest	methods		in	this	phase	ii	trial		patients	with	metastatic	platinum-refractory	ucmolecularly	selected	for	p16	loss	and	intact	rb	by	tumour	immunohistochemistryreceived	palbociclib	125	mg	p	o		daily	for	21	days	of	a	28-day	cycle		primaryendpoint	was	progression-free	survival	at	4	months	(pfs4)	using	a	simon'stwo-stage	design		next-generation	sequencing	including	rb	pathway	alterations	wasconducted	results		twelve	patients	were	enrolled	and	two	patients	(17%)	achieved	pfs4	withinsufficient	activity	to	advance	to	stage	2		no	responses	were	seen		median	pfswas	1	9	months	(95%	ci	1	8-3	7	months)	and	median	overall	survival	was	6	3	months(95%	ci	2	2-12	6	months)		fifty-eight	percent	of	patients	had	grade	â‰¥3hematologic	toxicity		there	were	no	cdkn2a	alterations	found	and	no	correlationof	rb	pathway	alterations	with	clinical	outcome	conclusions		palbociclib	did	not	demonstrate	meaningful	activity	in	selectedpatients	with	platinum-refractory	metastatic	uc		further	development	ofpalbociclib	should	only	be	considered	with	improved	integral	biomarker	selectionor	in	rational	combination	with	other	therapies	
